Pharm
Darunavir
search
Darunavir
, Darunavir/r, Prezista, Prezcobix
See Also
Anti-Retroviral Therapy
Protease Inhibitor
Indications
HIV Infection
(as part of combination therapy)
Contraindications
Age <3 years (toxicity risk)
Sulfonamide Allergy
(
Exercise
caution if used)
Mechanism
See
Protease Inhibitor
Medications
Darunavir (Prezista)
Tablets: 75, 150, 600 and 800 mg (600 mg tablet is generic)
Suspension: 100 mg/ml
Typically combined wiith
Ritonavir
as separate tablet (Darunavir/r)
All adverse effects and
Drug Interaction
s on this page assume administration with
Ritonavir
Combinations (with
Cobicistat
instead of
Ritonavir
)
Darunavir with
Cobicistat
(Prezcobix)
Darunavir,
Cobicistat
,
Emtricitabine
, and
Tenofovir Alafenamide
(Symtuza)
Dosing
Adult
Therapy naive or experienced without known Darunavir resistance substitutions
Darunavir 800 mg orally daily AND
Ritonavir
100 mg orally daily
Known Darunavir resistance substitutions, pregnancy or child weight >40 kg
Darunavir 600 mg orally twice daily AND
Ritonavir
100 mg orally twice daily
Dosing
Child (age 3 to 11 years, weight >=10 kg)
Contraindicated in age <3 years
Dosing off-label and per U.S.
HIV Treatment
guidelines (differs from FDA approved package insert dosing)
Indicated in therapy naive or experienced with or without known Darunavir resistance substitutions
Weight 10 to 11 kg: Darunavir 200 mg and
Ritonavir
32 mg, both taken orally twice daily
Weight 11 to 12 kg: Darunavir 220 mg and
Ritonavir
32 mg, both taken orally twice daily
Weight 12 to 13 kg: Darunavir 240 mg and
Ritonavir
40 mg, both taken orally twice daily
Weight 13 to 14 kg: Darunavir 260 mg and
Ritonavir
40 mg, both taken orally twice daily
Weight 14 to 15 kg: Darunavir 280 mg and
Ritonavir
48 mg, both taken orally twice daily
Weight 15 to 30 kg: Darunavir 375 mg and
Ritonavir
48 mg, both taken orally twice daily
Weight 30 to 40 kg: Darunavir 450 mg and
Ritonavir
100 mg, both taken orally twice daily
Weight >40 kg: Darunavir 600 mg and
Ritonavir
100 mg, both taken orally twice daily (adult dose)
Adverse Effects
See
Protease Inhibitor
for adverse effects attributed to the class
Rash (10%)
Stevens-Johnson Syndrome
risk
May be severe, requiring Darunavir to be discontinued
Hepatotoxicity
Monitor serum transaminases (AST, ALT) at baseline and for at least the first few months of therapy
Safety
Avoid in
Lactation
Pregnancy
Among preferred
Protease Inhibitor
s in pregnant women who are
HIV Treatment
naive
Drug Interactions
Multiple
Drug Interaction
s
See
Protease Inhibitor
As with other
Protease Inhibitor
s, check a formal
Drug Interaction
application before prescribing
Clarithromycin
Decrease
Clarithromycin
dose if
Creatinine Clearance
<60 ml/min
Azole Antifungal
s (esp.
Ketoconazole
,
Itraconazole
)
Limit to low dose (e.g. ketonazole 200 mg)
Voriconazole
Ritonavir
decreases
Voriconazole
levels and efficacy
Avoid concurrent use if possible
Oral Contraceptive
s
Use backup or alternative
Contraception
Drospirenone
Hyperkalemia
risk when used in combination
Monitor
Serum Potassium
if Drospirenone used with Darunavir
Didanosine
Didanosine
is buffered with decreased Darunavir oral absorption
Take
Didanosine
at least 1 hour before or 2 hours after Darunavir/r
Statin
s (esp.
Atorvastatin
,
Pravastatin
or
Rosuvastatin
)
Limit to lowest effective dose (e.g.
Atorvastatin
20 mg/day)
Contraindicated medications in combination with Darunavir
Dronedarone
Elbasavir-grazoprevir (
Zepatier
)
Everolimus
Glecaprevir-pibrentasvir (
Mavyret
)
Lopinavir
-
Ritonavir
Ranolazine
Saquinavir
Ticagrelor
Resources
Darunavir (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=814301f9-c990-46a5-b481-2879a521a16f
Darunavir with
Cobicistat
(Prezcobix, DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f
Darunavir,
Cobicistat
,
Emtricitabine
, and
Tenofovir Alafenamide
(Symtuza, DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=85a17d00-6b7c-41ea-a6b3-5ad924820dab
References
Hamilton (2020) Tarascon Pocket Pharmacopoeia
(2009) Treat Guidel Med Lett 7(78): 11-22 [PubMed]
Reust (2011) Am Fam Physician 83(12): 1443-51 [PubMed]
Type your search phrase here